Jadwiga Najib

Summary

Affiliation: Long Island University
Country: USA

Publications

  1. ncbi Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia
    Jadwiga Najib
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn 11201, and Department of Pharmacy St Luke s Roosevelt Hospital Center, New York, New York, USA
    Clin Ther 28:491-516. 2006
  2. ncbi The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults
    Jadwiga Najib
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA
    Clin Ther 31:142-76. 2009
  3. ncbi Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation
    Jadwiga Najib
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York 11201, USA
    Clin Ther 24:2022-50. 2002

Detail Information

Publications3

  1. ncbi Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia
    Jadwiga Najib
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn 11201, and Department of Pharmacy St Luke s Roosevelt Hospital Center, New York, New York, USA
    Clin Ther 28:491-516. 2006
    ..This paper reviews the pharmacologic and pharmacokinetic properties, clinical efficacy, and safety profile of the nonbenzodiazepine cyclopyrrolone agent eszopiclone in the management of adult patients with insomnia...
  2. ncbi The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults
    Jadwiga Najib
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, NY, USA
    Clin Ther 31:142-76. 2009
    ..Lisdexamfetamine dimesylate (LDX) is a once-daily medication approved by the US Food and Drug Administration for the management of attention-deficit/hyperactivity disorder (ADHD) in children (aged 6-12 years) and adults...
  3. ncbi Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation
    Jadwiga Najib
    Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York 11201, USA
    Clin Ther 24:2022-50. 2002
    ..The 67- and 200-mg micronized capsules can be considered equivalent to the 54- and 160-mg suprabioavailable tablets, respectively...